164 related articles for article (PubMed ID: 16848746)
21. Synthesis and biological evaluation of direct thrombin inhibitors bearing 4-(piperidin-1-yl)pyridine at the P1 position with potent anticoagulant activity.
de Candia M; Fiorella F; Lopopolo G; Carotti A; Romano MR; Lograno MD; Martel S; Carrupt PA; Belviso BD; Caliandro R; Altomare C
J Med Chem; 2013 Nov; 56(21):8696-711. PubMed ID: 24102612
[TBL] [Abstract][Full Text] [Related]
22. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF
J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022
[TBL] [Abstract][Full Text] [Related]
23. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.
Ewing WR; Becker MR; Manetta VE; Davis RS; Pauls HW; Mason H; Choi-Sledeski YM; Green D; Cha D; Spada AP; Cheney DL; Mason JS; Maignan S; Guilloteau JP; Brown K; Colussi D; Bentley R; Bostwick J; Kasiewski CJ; Morgan SR; Leadley RJ; Dunwiddie CT; Perrone MH; Chu V
J Med Chem; 1999 Sep; 42(18):3557-71. PubMed ID: 10479288
[TBL] [Abstract][Full Text] [Related]
24. Fibrin-targeted direct factor Xa inhibition: construction and characterization of a recombinant factor Xa inhibitor composed of an anti-fibrin single-chain antibody and tick anticoagulant peptide.
Hagemeyer CE; Tomic I; Jaminet P; Weirich U; Bassler N; Schwarz M; Runge MS; Bode C; Peter K
Thromb Haemost; 2004 Jul; 92(1):47-53. PubMed ID: 15213844
[TBL] [Abstract][Full Text] [Related]
25. Ecotin is a potent anticoagulant and reversible tight-binding inhibitor of factor Xa.
Seymour JL; Lindquist RN; Dennis MS; Moffat B; Yansura D; Reilly D; Wessinger ME; Lazarus RA
Biochemistry; 1994 Apr; 33(13):3949-58. PubMed ID: 8142399
[TBL] [Abstract][Full Text] [Related]
26. Surfing the Blood Coagulation Cascade: Insight into the Vital Factor Xa.
Núñez-Navarro NE; Santana FM; Parra LP; Zacconi FC
Curr Med Chem; 2019; 26(17):3175-3200. PubMed ID: 29376487
[TBL] [Abstract][Full Text] [Related]
27. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor.
Rupin A; Mennecier P; Lila C; de Nanteuil G; Verbeuren TJ
Thromb Haemost; 1997 Oct; 78(4):1221-7. PubMed ID: 9364988
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of 3,4-diaminobenzoyl derivatives as factor Xa inhibitors.
Yang J; Su G; Ren Y; Chen Y
Eur J Med Chem; 2015 Aug; 101():41-51. PubMed ID: 26114810
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitor.
Nishida H; Miyazaki Y; Kitamura Y; Ohashi M; Matsusue T; Okamoto A; Hosaka Y; Ohnishi S; Mochizuki H
Chem Pharm Bull (Tokyo); 2001 Oct; 49(10):1237-44. PubMed ID: 11605647
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in serine protease inhibitors as anticoagulant agents.
Prezelj A; Anderluh PS; Peternel L; Urleb U
Curr Pharm Des; 2007; 13(3):287-312. PubMed ID: 17313362
[TBL] [Abstract][Full Text] [Related]
31. Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT.
Sielaff F; Böttcher-Friebertshäuser E; Meyer D; Saupe SM; Volk IM; Garten W; Steinmetzer T
Bioorg Med Chem Lett; 2011 Aug; 21(16):4860-4. PubMed ID: 21741839
[TBL] [Abstract][Full Text] [Related]
32. X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition.
Brandstetter H; Kühne A; Bode W; Huber R; von der Saal W; Wirthensohn K; Engh RA
J Biol Chem; 1996 Nov; 271(47):29988-92. PubMed ID: 8939944
[TBL] [Abstract][Full Text] [Related]
33. Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants?
Papadaki S; Tselepis AD
Angiology; 2019 Nov; 70(10):896-907. PubMed ID: 31010298
[TBL] [Abstract][Full Text] [Related]
34. Factor Xa activation of factor V is of paramount importance in initiating the coagulation system: lessons from a tick salivary protein.
Schuijt TJ; Bakhtiari K; Daffre S; Deponte K; Wielders SJ; Marquart JA; Hovius JW; van der Poll T; Fikrig E; Bunce MW; Camire RM; Nicolaes GA; Meijers JC; van 't Veer C
Circulation; 2013 Jul; 128(3):254-66. PubMed ID: 23817575
[TBL] [Abstract][Full Text] [Related]
35. Potent direct inhibitors of factor Xa based on the tetrahydroisoquinoline scaffold.
Al-Horani RA; Mehta AY; Desai UR
Eur J Med Chem; 2012 Aug; 54():771-83. PubMed ID: 22770607
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological characterization of a novel factor Xa inhibitor, FXV673.
Chu V; Brown K; Colussi D; Gao J; Bostwick J; Kasiewski C; Bentley R; Morgan S; Guertin K; Pauls HW; Gong Y; Zulli A; Perrone MH; Dunwiddie CT; Leadley RJ
Thromb Res; 2001 Aug; 103(4):309-24. PubMed ID: 11562341
[TBL] [Abstract][Full Text] [Related]
37. Functional characterisation of vizottin, the first factor Xa inhibitor purified from the leech Haementeria vizottoi.
Oliveira DG; Alvarez-Flores MP; Lopes AR; Chudzinski-Tavassi AM
Thromb Haemost; 2012 Sep; 108(3):570-8. PubMed ID: 22782262
[TBL] [Abstract][Full Text] [Related]
38. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
Bhunia SS; Roy KK; Saxena AK
J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
[TBL] [Abstract][Full Text] [Related]
39. Beyond heparinization: design of highly potent thrombin inhibitors suitable for surface coupling.
Steinmetzer T; Baum B; Biela A; Klebe G; Nowak G; Bucha E
ChemMedChem; 2012 Nov; 7(11):1965-73. PubMed ID: 22907907
[TBL] [Abstract][Full Text] [Related]
40. Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.
Shi Y; O'Connor SP; Sitkoff D; Zhang J; Shi M; Bisaha SN; Wang Y; Li C; Ruan Z; Lawrence RM; Klei HE; Kish K; Liu EC; Seiler SM; Schweizer L; Steinbacher TE; Schumacher WA; Robl JA; Macor JE; Atwal KS; Stein PD
Bioorg Med Chem Lett; 2011 Dec; 21(24):7516-21. PubMed ID: 22041058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
